Introduction {#sec1-1}
============

Adults who suffered from idiopathic nephrotic syndrome in childhood have an increased risk of atherosclerosis.\[[@ref1][@ref2]\] Studies in the pediatric population have revealed that the risk factors of atherosclerosis occur in patients having nephrotic syndrome in various disease stages, which lead to the assumption that such children are predisposed to accelerated atherosclerosis.\[[@ref1]\] Recently, several novel risk factors of atherosclerosis have been described. These risk factors include raised homocysteine, asymmetric dimethylarginine, endothelin-1, proteins of chronic inflammatory process, pro-thrombotic factors, and adhesion molecules.\[[@ref3]\] In an analytical study, we recently demonstrated that the levels of soluble thrombomodulin, tissue plasminogen activator, plasminogen activator inhibitor 1, and von-Willebrand factor are raised in children with first episode of nephrotic syndrome (FENS), pointing towards endothelial dysfunction.\[[@ref4]\]

Homocysteine is a sulfhydryl containing amino acid, a homologue of cysteine with one additional methylene group in its side chain.\[[@ref5]\] Hyperhomocystenemia is an independent risk factor for coronary heart disease, andnormotensive patients with hyperhomocysteinemia display endothelial dysfunction.\[[@ref6][@ref7]\] In plasma, 70--80% of homocysteine occurs in a protein-bound form, and the remaining 20--30% occurs in free form as oxidized cysteine or homocysteine; free reduced homocysteine contributes to 1% of the total levels.\[[@ref8]\] Elevated homocysteine levels are found in almost one-third of all patients with atherosclerosis, and levels more than 12% above the upper limit are associated with a three-fold increase in the risk of myocardial infarction.\[[@ref9][@ref10]\] Folic acid supplementation can reduce homocysteine levels and improve endothelial dysfunction in children with chronic renal failure.\[[@ref11]\]

We have found that total homocysteine levels are markedly elevated in urine of the children with idiopathic nephrotic syndrome along with vitamin B~12~ and folic acid.\[[@ref12]\] Chambers *et al*. reported that free plasma homocysteine concentrations may be a more accurate index of the biological activity of homocysteine *in vivo*.\[[@ref13][@ref14]\] Evidence to support the assertion of plasma homocysteine levels playing a significant role in predicting endothelial dysfunction eventually predisposing to atherosclerotic events also comes from *in-vitro* data. These studies show that free homocysteine species inactivate NO, promote the generation of copper-catalyzed, oxygen-derived free radicals, induce tissue factor release, and cause endothelial injury.\[[@ref15][@ref16][@ref17][@ref18]\] Martijn *et al*. conducted a prospective study in a cohort of 379 patients hospitalized for acute coronary syndrome showing that plasma-free homocysteine level is a strong and independent predictor of recurrent acute myocardial infarction, stroke, or death due to cardiovascular causes.\[[@ref19]\] Our study was designed with a primary objective to measure plasma free homocysteine levels in children with FENS compared to controls. The secondary objective was to measure levels in drug-induced remission and in steroid resistant states.

Materials and Methods {#sec1-2}
=====================

Study design and patient groups {#sec2-1}
-------------------------------

This was an analytical study with a longitudinal follow-up conducted in a tertiary care hospital in New Delhi from November 2012 to July 2014. The study was approved by the institutional review board and a written informed consent was taken from all the participants. The study group included children with FENS aged 1--16 years and 30 age and gender-matched healthy controls coming to the outpatient department for a health certificate needed for joining swimming classes or dance classes. Children who had secondary nephrotic syndrome, signs of thromboembolic complications, bleeding diathesis, on drugs known to affect endothelial function, pre-existing hypertension, diabetes mellitus, recent history of blood transfusion, who had taken vitamin B~12~/folate within the last 2 weeks and who refused to give an informed consent were excluded from the study. The patients were enrolled at the onset of the disease and were followed for 1 year. Samples were collected at the time of initial presentation, in remission, and before starting second-line drugs. Standard laboratory methods were used to analyze serum albumin, cholesterol, and other laboratory parameters. Guidelines by the Indian Society of Pediatric Nephrology were used for the diagnosis and treatment of steroid sensitive nephrotic syndrome (SSNS), and steroid-resistant nephrotic syndrome (SRNS).\[[@ref20][@ref21]\] Initial episode of nephrotic syndrome was treated with prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy was subsequently discontinued. Patients who failed to achieve remission after 4 weeks of prednisolone at a dose of 2 mg/kg/day were diagnosed as SRNS. Renal biopsy was performed in all steroid-resistant children. The primary outcome was to compare the levels of free homocysteine in children with FENS and controls. Secondary outcome measure was to observe the levels of plasma-free homocysteine in children with FENS at 12 weeks in remission.

Measurement of free homocysteine {#sec2-2}
--------------------------------

Blood samples were collected in lithium heparin vials and centrifuged immediately at 2800 g for 10 min. Two hundred microlitres of plasma was taken in three alliquots each and then 100 μl of perchloric acid was added and centrifuged at 10000 g for 30 min. The supernatant fluid thus obtained was stored at −80°C until analyzed. Free homocysteine was measured using high-performance liquid chromatography (HPLC) machine present at the IGIB. In this method, the samples were treated with sodium borohydrate to reduce disulfide bonds. Amyl alcohol controls foaming and borohydrate reduction of disulfide bonds releases homocysteine and cleaves low molecular weight oxidized forms of homocysteine such as homocysteine, cysteinylhomocysteine, and glutathionylhomocysteine. The thiol group of free homocysteine was then derivatized with the fluorescent adduct monobromobimane to form a fluorescent homocysteine-bimane conjugate. Subsequently, perchloric acid was added and centrifuged. The supernatant fluid was then neutralized with Tris and injected into HPLC. Homocysteine bimane was resolved from other thiol bimane conjugates on a reverse-phase column and detected fluorometrically. Results were quantified by taking the area of the homocysteine-bimane peak and calculating its concentration using a regression equation from a standard curve.

Statistical analysis {#sec2-3}
--------------------

Data was analyzedusing Strata 11.1(Stata Corp, 4905 Lakeway Drive, College Station, Texas USA) and presented as frequency (%), mean (SD), and median (IQR), as applicable. Categorical variable (sex) was compared in the two groups using Fischer\'s exact test. Continuous variables with a normal distribution were compared among the groups using one-way analysis of variance (ANOVA) followed by *post hoc* comparison using Bonferroni test continuous, and non-normal variables were evaluated by Wilcoxon\'s rank sum test/Kruskal--Wallis test followed by multiple comparison using Wilcoxan\'s rank sum test with Bonferroni correction. Changes in continuous variables were assessed by Wilcoxon\'s sign rank test. Corelation of homocysteine with other variables was assessed by spearman correlation coefficient "(rho)." *P* value of \<0.05 was considered significant.

Results {#sec1-3}
=======

Twentynine children with FENS were included in the study. Baseline characteristics in children with SSNS (*N* = 22), SRNS (*N* = 7) and controls groups has been reported in [Table 1](#T1){ref-type="table"}. Children in SSNS group had significantly lesser height for age than controls (*P* = 0.012), significantly higher weight for their age than controls (*P* = 0.005) and SRNS patients (*P* = 0.019). Systolic blood pressure was significantly higher in SSNS patients (*P* = 0.006) and SRNS patients (*P* = 0.036) compared to controls \[[Table 1](#T1){ref-type="table"}\]. All patients with SRNS had minimal change disease on histopathological examination.

###### 

Demographic profile of patients and controls

                                   SSNS (mean±SD) (*n*=22)   SRNS (mean±SD) (*n*=7)   Control (mean±SD) (*n*=30)   *P*
  -------------------------------- ------------------------- ------------------------ ---------------------------- ---------
  Age (years)                      5.55±3.54                 8.28±4.40                5.59±3.81                    0.354
  ^\#^Gender (male/female)         13/9                      3/4                      16/14                        0.759
  Height (cms)                     104.27±20.07              112.43±22.62             105.33±21.264                0.584
  Height z score                   -1.38±0.99                -2.37±1.18               -1.02±1.39                   0.039
  Weight (kgs)                     18.68±8.56                19.85±7.80               17.07±8.950                  0.421
  Weight z score                   -0.87±1.02                -2.31±2.2                -1.99±1.37)                  0.008
  BMI (kg/m^2^)                    18.68±8.56                19.86±7.80               14.400±2.98                  0.834
  BMI z score                      -0.09±1.57                -1.6±1.93                -2.5±3.66                    0.021
  Systolic BP z score              0.87±1.08                 1.08±0.87                0.25±0.63                    0.020
  Diastolic BP z score             (1.32±1.10)               (1.26±0.68)              (0.95±0.48)                  0.270
  Total protein (g/dl)             3.86±0.51                 3.9±0.40                 6.807±0.726                  \<0.001
  S.Albumin (g/dl)                 1.75±0.28                 1.7±0.33                 4.190±0.377                  \<0.001
  Urine protein creatinine ratio   10.68±±15.09              10.81±5.17               0.218±0.122                  \<0.001
  Total Cholesterol (mg/dl)        433.95±128.91             367.71±138.88            133.37±27.987                \<0.001
  Creatinine (µmole/L)             39.78±15.9                74.27±60.11              42.69±9.28                   0.219
  eGFR (ml/min/1.732m^2^)          113.66±49.73              81.94±46.68              94.967±25.189                0.296

All the values are expressed as Mean±SD \*Test name: one way annova - for normally distributed data; Kruskal wallis test - for skewed data ; ^\#^categorical variable -- Fischer exact test. FENS: First episode nephrotic syndrome, SSNS: Steroid sensitive nephrotic syndrome, SRNS: Steroid resistant nephotic syndrome, cms: Centimetres, kgs: Kilograms, mmHg: Millimetres of mercury, Kg/m^2^: Kilograms per metre squared, SBP/DBP: Systolic/Diastolic blood pressure, BMI: Body mass index, eGFR: Estimated glomerular filtration rate

Free homocysteine levels were significantly elevated in children with FENS at disease onset (*P* \< 0.001), at 12 weeks of steroid-induced remission (*P* \< 0.001), and in steroid-resistant states (*P* \< 0.001) compared to controls \[[Table 2](#T2){ref-type="table"}\]. Free homocysteine levels decreased after 12 weeks of drug-induced remission compared to the levels at onset but was not statistically significant (*P* = 0.06) \[[Table 2](#T2){ref-type="table"}\]. Plasma total homocysteine levels were elevated in SSNS (median = 4.053; *P* \< 0.001), SRNS at disease onset (median = 9.254; *P* = 0.004) compared to controls (median = 3.433). The proportion of free homocysteine compared to the total homocysteine was significantly higher in first episode nephrotic syndrome compared to controls (median 24.47 vs 6.22; *P* \< 0.001). Free homocysteine levels correlated positively with serum total cholesterol (*P* = 0.005; *r* = 0.362) and negatively with serum albumin (*P* = 0.032; 0.281). There was no correlation of free homocysteine with age (*P* = 0.078; *r* = 0.333), systolic blood pressure (*P* = 0.975; *r* = −0.006), diastolic blood pressure (*P* = 0.924; *r* = −0.018), BMI (*P* = 0.949; *r* = 0.012), and urinary protein (*P* = 0.892; *r* = 0.026).

###### 

Free homocysteine levels in cases and controls

                                                     SSNS (at onset) (*n*=22)   SSNS (at 12 weeks remission) (*n*=22)   SRNS (at onset) (*n*=7)   SRNS (at 4 weeks) (*n*=7)   Controls (*n*=30)
  -------------------------------------------------- -------------------------- --------------------------------------- ------------------------- --------------------------- -------------------
  Free homocysteine (micromol/L) median (IQ range)   1.946 (1.53-2.71)          1.606 (0.96-2.14)                       2.262 (1.53-2.74)         2.443 (2.24-2.74)           0.784 (0.57-1.16)
  *P*                                                \<0.001\*                  \<0.001\*                               0.760\*\*                 0.499\*\*\*                 

\*Statistical difference as compared to controls and Wilcoxon's ranksum test applied. \*\*Statistical difference as compared to SSNS group at onset and Wilcoxon's ranksum test applied. \*\*\*Statistical difference as compared to SRNS at onset and Wilcoxon's sign rank test apllied SSNS: Steroid sensitive nephrotic syndrome, SRNS: Steroid resistant nephotic syndrome

Discussion {#sec1-4}
==========

In this study, we found that the level of free homocysteine in plasma was significantly elevated in children with FENS compared to controls. Similar findings have also been reported by Tkaczyk *et al*.;\[[@ref22]\] however, because the patient population was not homogenous, we selected only FENS in our study. We recently reported that children with FENS have plasma total homocysteine levels comparable to controls; however, this was associated with a marked increase in urinary homocysteine excretion.\[[@ref12]\] This is plausible as most of the homocysteine in plasma is bound to albumin. There was concurrent increased urinary excretion of vitamin B~12~ and folate which normalized during remission. Elevation of urinary homocysteine was because of the presence of albumin-bound homocysteine in urine. Children with FENS had low plasma levels of vitamin B~12~ and folate, a finding previously reported by Podda *et al*.\[[@ref23]\] It is well known that vitamin B~12~ and folate deficiency causes hyperhomocysteinemia by interfering with the methylation pathway.\[[@ref24]\] Low plasma vitamin B~12~ and folate is seen in children with idiopathic NS because of increased urinary loss.\[[@ref12]\]

Free homocysteine species inactivate NO, promote the generation of oxygen-derived free radicals, induce tissue factor release, and cause endothelial cell injury.\[[@ref22]\] Endothelial dysfunction in the presence of elevated plasma total homocysteine levels may be mediated by oxidative stress by impairing intracellular glutathione peroxidase-1 activity and expression.\[[@ref25]\] This effect reduces the ability of the endothelial cell to detoxify itself of hydroxyl radicals and permits further oxidative damage. Previous studies investigating homocysteine and vascular disease have relied on total plasma homocysteine as the sole index of homocysteine status. Chambers *et al*. reported that reduced free homocysteine was closely associated with endothelial dysfunction during oral methionine and oral homocysteine loading. They found an inverse relationship between free homocysteine peak concentration and flow-mediated dilatation which is a marker of endothelial function.\[[@ref14]\] Free homocysteine rather than total homocysteine was found to be an accurate marker for the prognosis of patients with acute coronary symptoms.\[[@ref19]\] Hence, elevated free homocysteine levels in children with FENS poses a risk of endothelial dysfunction.

The level of free homocysteine in the cases decreased after 12 weeks of drug-induced remission but it was insignificant and remained higher than the controls, pointing that children are at a risk of endothelial dysfunction even after drug-induced remission. The level of free homocysteine was persistently elevated in steroid-resistant patients and was higher indicating a higher risk of endothelial dysfunction. Long-term adverse effects of raised free homocysteine levels in children with idiopathic nephrotic syndrome also needs to be evaluated in well-designed studies. Thus, free homocysteine might play a significant role in causing endothelial dysfunction in children with idiopathic nephrotic syndrome. Modulation of endothelial dysfunction in children with FENS may be considered a therapeutic strategy to decrease the risk of future adverse cardiovascular events.

To conclude, we have shown risk of endothelial dysfunction due to elevated free homocysteine levels in short term in children with FENS. Long-term prospective studies are needed in children with idiopathic nephrotic syndrome. The limitations of our study are small sample size, short term follow up, and single-centred analysis; nevertheless, our study showed that children with FENS have higher plasma free homocysteine levels and are at a risk of endothelial dysfunction.
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